Literature DB >> 21807916

Osteonecrosis of the knee and related conditions.

Michael A Mont1, David R Marker, Michael G Zywiel, John A Carrino.   

Abstract

Osteonecrosis (ON) of the knee is a progressive disease that often leads to subchondral collapse and disabling arthritis. Recent studies have identified three distinct pathologic entities, all of which were previously described as knee ON: secondary ON, spontaneous ON of the knee, and postarthroscopic ON. Radiographic and clinical assessment is useful for differentiating these conditions, predicting disease progression, and distinguishing these conditions from other knee pathologies. The etiology, pathology, and pathogenesis of secondary ON of the knee are similar to those found at other sites (eg, hip, shoulder). Spontaneous ON is a disorder of unknown etiology. Postarthroscopic ON has been described as an infrequent but potentially destructive complication. Various treatment modalities (eg, core decompression, bone grafting, high tibial osteotomy, arthroplasty), have been used with varying degrees of success for each type of ON. Secondary ON frequently progresses to end-stage disease, and early surgical intervention is recommended. Initial management of spontaneous ON of the knee and postarthroscopic ON is typically nonsurgical, with observation for clinical or radiographic progression.

Entities:  

Mesh:

Year:  2011        PMID: 21807916     DOI: 10.5435/00124635-201108000-00004

Source DB:  PubMed          Journal:  J Am Acad Orthop Surg        ISSN: 1067-151X            Impact factor:   3.020


  34 in total

1.  Osteochondral allograft.

Authors:  Arissa M Torrie; William W Kesler; Joshua Elkin; Robert A Gallo
Journal:  Curr Rev Musculoskelet Med       Date:  2015-12

2.  Spontaneous osteonecrosis of the knee: an unusual cause of knee pain.

Authors:  Raju Vaishya; Vipul Vijay; Abhishek Vaish
Journal:  BMJ Case Rep       Date:  2014-04-30

Review 3.  Bone marrow lesions and subchondral bone pathology of the knee.

Authors:  Elizaveta Kon; Mario Ronga; Giuseppe Filardo; Jack Farr; Henning Madry; Giuseppe Milano; Luca Andriolo; Nogah Shabshin
Journal:  Knee Surg Sports Traumatol Arthrosc       Date:  2016-04-13       Impact factor: 4.342

4.  Characteristics, management, and outcomes of spontaneous osteonecrosis of the knee in Indian population.

Authors:  Nishit Bhatnagar; Siddharth Sharma; Virender Kumar Gautam; Ajeet Kumar; Anurag Tiwari
Journal:  Int Orthop       Date:  2018-03-18       Impact factor: 3.075

Review 5.  Osteonecrosis of the knee: review.

Authors:  Ammar R Karim; Jeffrey J Cherian; Julio J Jauregui; Todd Pierce; Michael A Mont
Journal:  Ann Transl Med       Date:  2015-01

6.  Management of osteonecrosis of proximal tibia using trabecular osteonecrotic rods.

Authors:  Biyyam Rao; Tamer Kamal
Journal:  J Clin Orthop Trauma       Date:  2012-06-16

7.  Atraumatic Medullary Osteonecrosis of the Tibia and Femur Treated With Intraosseous Orthobiologics.

Authors:  Adam Street; Mairin A Jerome; Christopher J Williams
Journal:  Cureus       Date:  2021-07-27

8.  Subchondral stem cell therapy versus contralateral total knee arthroplasty for osteoarthritis following secondary osteonecrosis of the knee.

Authors:  Philippe Hernigou; Jean Charles Auregan; Arnaud Dubory; Charles Henri Flouzat-Lachaniette; Nathalie Chevallier; Helene Rouard
Journal:  Int Orthop       Date:  2018-03-27       Impact factor: 3.075

9.  Effect of ibandronate on spontaneous osteonecrosis of the knee: a randomized, double-blind, placebo-controlled trial.

Authors:  C Meier; C Kraenzlin; N F Friederich; T Wischer; L Grize; C R Meier; M E Kraenzlin
Journal:  Osteoporos Int       Date:  2013-11-22       Impact factor: 4.507

10.  Safety and efficacy of matrix-associated autologous chondrocyte implantation with spheroid technology is independent of spheroid dose after 4 years.

Authors:  Philipp Niemeyer; Volker Laute; Wolfgang Zinser; Thilo John; Christoph Becher; Peter Diehl; Thomas Kolombe; Jakob Fay; Rainer Siebold; Stefan Fickert
Journal:  Knee Surg Sports Traumatol Arthrosc       Date:  2020-01-02       Impact factor: 4.342

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.